IRF4 and neoplasm: Our findings demonstrated that IRF4‐mediated SOX9 induction in BCL2‐overexpressing DLBCL was associated with tumour progression, suggesting the potential therapeutic implication of the IRF4‒SOX9 signalling axis in this type of DLBCL.